Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 13/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3592059 | 0.85 | PTGER4 (0.48) | PTGER4ATMMAPTKDM4EALDH1A1 | |
| SCHEMBL29092663 | 0.81 | BRD4 (0.47) | PTGER4ATMKDM4EMPO | |
| SCHEMBL3583917 | 0.81 | MPO (0.59) | PTGER4ATMKDM4EALDH1A1MPO | |
| SCHEMBL28868180 | 0.80 | ATM (0.43) | PTGER4ATMMAPTMPO | |
| SCHEMBL28495961 | 0.80 | ELANE (0.49) | ATMMAPTKDM4EALDH1A1 | |
| SCHEMBL29445732 | 0.79 | EYA3 (0.44) | PTGER4ATMMAPTL3MBTL1 | |
| SCHEMBL3589934 | 0.78 | KDM5A (0.41) | PTGER4ATMMAPTKDM4E | |
| SCHEMBL29445731 | 0.76 | PTGER4 (0.54) | PTGER4MAPTKDM4EALDH1A1 | |
| SCHEMBL25153638 | 0.74 | MPO (0.45) | PTGER4ATMMAPTKDM4EALDH1A1 | |
| SCHEMBL21176888 | 0.74 | SLC22A12 (0.47) | PTGER4ATMMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507528-B2 | 2-alkyl-indazole compounds for the treatment of certain cns-related disorders | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2013-08-13 | — | — | US | disclosed |
| CN-101558057-B | 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders | ACRAF | 2013-05-01 | — | — | CN | disclosed |
| EP-2099780-B1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | ACRAF (IT) | 2013-01-09 | — | — | EP | disclosed |
| US-20100056573-A1 | 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2010-03-04 | — | — | US | disclosed |
| CN-101558057-A | 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders | ACRAF (IT) | 2009-10-14 | — | — | CN | disclosed |
| EP-2099780-A1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008061688-A1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056573-A1 | 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | CYP11B2, CYP1A2, INA | PTGER4 3047/4885ATM 2184/4885MAPT 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.